Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Osimertinib. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111394747A reveals a novel electrochemical route for 2-acyloxy aniline derivatives, offering significant cost reduction and greener API manufacturing processes.
Patent CN116283922A reveals a Bronsted acid-catalyzed method for EGFR inhibitor intermediates, offering higher yields and metal-free processing for reliable supply chains.
Novel patent CN106543060A offers streamlined Osimertinib Mesylate synthesis. Enhances supply chain reliability and cost reduction in pharmaceutical manufacturing.
Patent CN106366072B details a high-yield convergent synthesis route for Osimertinib, offering cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN109134435A details a high-yield Osimertinib synthesis using cobalt catalysis. This method offers significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN113651800A reveals a high-yield route for Oxitinib Mesylate, offering cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN104817541A reveals a high-yield synthetic route for AZD9291 intermediates. This report analyzes cost reduction in pharmaceutical manufacturing and supply chain reliability for global buyers.
Patent CN107935997A reveals a cost-effective Osimertinib route avoiding expensive chloropyrimidine. Enhance supply chain reliability with scalable manufacturing.
Patent CN106366022B reveals high-yield AZD9291 intermediate synthesis. Offers cost reduction in API manufacturing and supply chain reliability for global buyers.
Discover how advanced cuprous bromide activation and palladium-catalyzed hydrogenation reduce solid waste by 90% while achieving 99.8% purity and 72% yield for AZD9291 production.